Bolt Biotherapeutics Inc Ordinary Shares BOLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BOLT is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.16
- Day Range
- $1.12–1.20
- 52-Week Range
- $0.84–2.03
- Bid/Ask
- $1.11 / $1.14
- Market Cap
- $43.08 Mil
- Volume/Avg
- 115,798 / 135,195
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.57
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 100
- Website
- https://www.boltbio.com
Valuation
|
Metric
|
BOLT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.39 |
Price/Sales | 5.57 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BOLT
|
|---|---|
Quick Ratio | 5.00 |
Current Ratio | 5.17 |
Interest Coverage | — |
Quick Ratio
BOLT
Profitability
|
Metric
|
BOLT
|
|---|---|
Return on Assets (Normalized) | −31.24% |
Return on Equity (Normalized) | −42.10% |
Return on Invested Capital (Normalized) | −40.86% |
Return on Assets
BOLT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pkcwnsjys | Mgvk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mkqvxhvp | Vmvrvs | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tqtxtxmp | Rpyrlxw | $97.8 Bil | |
MRNA
| Moderna Inc | Dzmnqnpv | Nbsz | $38.8 Bil | |
ARGX
| argenx SE ADR | Dbyvwjgz | Vxlg | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Mvygcvgzk | Zqhc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yxblhxk | Vcktnz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wzjwfmy | Vwjlwtz | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vngqwhdjwr | Rzxjzyd | $12.5 Bil | |
INCY
| Incyte Corp | Yklwmglkr | Khyktrn | $11.5 Bil |